Opinions
Robert McWhirter
Acasti Pharma
ACST-X
RISKY
Dec 27, 2019
They're working on a phase two test of a new drug, but the results are delayed, which has hammered the stock by half, though it's moved up 16% today. Results should be released in mid/late-January and he expects them to be positive. The drug will address a huge population who suffers high cholesterol. He sees a $10 target price, if the result is good and all goes well. Very speculative.
$2.870
Stock price when the opinion was issued
Consumer Products
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
STRONG BUY
It's finally breaking out after going nowhere for a while. They're doing phase 3 trials now on their drug and should complete the results by December. That's why investors are pushing this stock up. He expects good results and be accretive. A $200 million company worth north of $1 billion. Caveat: biotech stocks are volatile.
Consumer Products
BUY
They use the lipid from krill oil to strengthen action of another drug. Early indications seem very promising. The results should be out soon. One batch before the end of the year, and another in the new year. If the trial is successful, we could see a significant increase in the price.
Consumer Products
SELL
It highlights the pharma industry. In Canada there are a lot of tax credits that are applicable to Canadian Pharma companies. You can't say this is predictable. They went through the trials and it did not work. Phase three is for that. They still have some cash and some science. Stocks in this position usually flat lines for a while. He feels it is better to come out and get back in later.
Consumer Products
WAIT
COMMENT
The krill oil lipid trial did not work as expected. The overall portfolio is quite attractive. Over the coming year, there may be opportunities. However, there are other opportunities in other companies like ATE, which he owns.
Consumer Products
Advertising